🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in India / NCT03775460
Active, not recruiting Not applicable

Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum

NCT03775460 · tracked via the Priya Life Science India tracker
Sponsor
London School of Hygiene and Tropical Medicine
Phase
Not applicable
Started
2023-01-15
Last updated
2025-09-10

Condition(s) studied

Erythema Nodosum Leprosum

Investigational drug(s) / intervention(s)

MethotrexatePlaceboPrednisolone

Methotrexate: Participants in the intervention group will receive methotrexate along side prednisolone

Placebo: Participants in the control arm will receive placebo along side prednisolone

Prednisolone: Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks

Study summary

Erythema Nodosum Leprosum (ENL) is a painful, debilitating complication of leprosy. Patients often require high doses of corticosteroids for prolonged periods. Thalidomide is expensive and not available in most countries. The use of corticosteroids for long periods is associated with adverse effects and mortality. It is a priority to identify alternative agents to treat ENL. Methotrexate (MTX) is a cheap, widely used medication which has been reported to be effective in ENL resistant to steroids and thalidomide.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria:: ALL OF THE FOLLOWING SIX CRITERIA MUST BE MET IN ORDER FOR AN INDIVIDUAL TO BE ELIGIBLE (ONLY ONE OF 6A TO 6D NEED BE MET): 1. Individuals who diagnosed with leprosy complicated by ENL 2. Individuals with ENL aged 18-60 years old 3. Individuals with ENL deteriorating symptoms 4. Individuals with 10 or more tender, papular or nodular ENL skin lesions 5. Individuals with an EESS score of at least 9 6. Individuals with ENL on: 1. No current anti- ENL treatment 2. Prednisolone up to 30mg per day (if ACUTE) or Prednisolone 10-30mg (inclusive) per day (if RECURRENT/ CHRONIC) or equivalent alternative corticosteroid dose OR 3. Thalidomide or other non-steroidal anti-ENL medication OR 4. A combination of prednisolone (up to 30mg) and another non-steroidal anti-ENL medication (thalidomide, clofazimine, azathioprine, pentoxifylline, ciclosporin, minocycline) Exclusion criteria: 1. Individuals who were first diagnosed with ENL more than 4 years prior to enrolment 2. Individuals less than 18 years old or older than 60 years 3. Individuals weighing less than 35kg 4. Individuals with 9 or fewer tender, popular or nodular ENL skin lesions 5. Individuals with an EESS score of 8 or less 6. Women of child bearing capacity who decline to use two forms of adequate contraception and men who decline to use two forms of adequate contraception 7. Pregnant or breastfeeding women 8. Individuals with recurrent or chronic ENL who deteriorate on a dose of prednisolone less than 10 mg or more than 30 mg 9. Individuals who have taken methotrexate by any route for the last 12 weeks 10. Individuals with a hypersensitivity to methotrexate or a recognised contraindication ( please see Methotrexate information sheet) 11. Individuals currently diagnosed with Type 1 reaction or Lucio's phenomenon 12. Individuals with the severe abnormalities in screening investigations 13. Positive serology for HIV, Hepatitis B or C 14. Evidence of tuberculosis or pulmonary fibrosis 15. A history of chronic liver disease or excessive alcohol or illicit substance consumption 16. Individuals with severe inter-current infections, uncontrolled diabetes, active peptic ulcer disease, untreated malignancy 17. Individuals unable to attend regularly for assessment or monitoring

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
TMLI Bangladesh/ DBLM hospital Dhaka Bangladesh
FIOCRUZ Rio de Janeiro Brazil
ALERT Addis Ababa Ethiopia
The Leprosy Mission Trust Delhi India
Bombay Leprosy Project Mumbai India
Soetomo Hospital Surabaya Indonesia
Anandaban Hospital Kathmandu Nepal

More London School of Hygiene and Tropical Medicine trials in India

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03775460 on ClinicalTrials.gov ↗ ← All trials in India